CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2 negative advanced breast cancer: A rapid health technology assessment

OBJECT: Based on the best available evidence, rapid health technology was used to assess 4 CDK4/6 inhibitors approved for marketing in China. This assessment aims to provide a reference basis for the selection of drugs by medical institutions in China and to promote the rational use of drugs in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Hangye, Chen, Yaqing, Xie, Zeyu, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553163/
https://www.ncbi.nlm.nih.gov/pubmed/37800838
http://dx.doi.org/10.1097/MD.0000000000035487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553163/
https://www.ncbi.nlm.nih.gov/pubmed/37800838
http://dx.doi.org/10.1097/MD.0000000000035487

Ejemplares similares